2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- -92.50%1-Year Change
- Medical Instruments & SuppliesIndustry
Cuprina Hldgs-A (CUPR)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 84
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Cuprina Holdings Falls 22% After 112% Rally — Here's Why CUPR Stock Is Trending
Cuprina Holdings (NASDAQ: CUPR) surged 111.84% intraday to $8.41 after receiving FDA 510(k) clearance for MEDIFLY Maggots, a maggot debridement product for non-healing wounds. The stock subsequently fell 22.47% to $6.52 in after-hours trading. MEDIFLY Maggots is the first maggot debridement product using Lucilia cuprina species to receive FDA clearance, giving the Singapore-based biomedical company commercial rights to both maggot species used in the therapy.
06/16/2026, 3:20 AM • Benzinga
What's Going On With Cuprina Stock Monday?
Cuprina Holdings (NASDAQ: CUPR) stock experienced muted trading on Monday after surging 64.73% on Friday following the company's announcement that it regained compliance with Nasdaq Capital Market listing requirements. The Singapore-based biomedical company had previously faced delisting risk due to failing to maintain a minimum bid price of $1 per share for 30 consecutive business days. With the immediate catalyst priced in, traders adopted a wait-and-see approach, with shares down 1.76% in premarket trading.
06/15/2026, 8:30 AM • Benzinga
Cuprina Holdings completed a 1-for-8 reverse stock split on May 27, 2026, and requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination. The company failed to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share despite having until May 26, 2026 to do so. The hearing request will stay the suspension of trading pending the Panel's decision, and the company expects the share consolidation to bring its bid price into compliance.
05/29/2026, 12:55 PM • GlobeNewswire
Cuprina Holdings announces 1-for-8 Share Consolidation
Cuprina Holdings (Nasdaq: CUPR) announced a 1-for-8 share consolidation effective May 27, 2026, to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market. The consolidation was approved by the board on April 21, 2026, and shareholders on May 14, 2026. The company's par value will increase from $0.001 to $0.008 per share, with no change to shareholders' percentage ownership except for fractional share adjustments.
05/22/2026, 10:50 AM • GlobeNewswire
The Schall Law Firm is investigating Cuprina Holdings (Cayman) Limited for potential securities law violations, including allegations of false or misleading statements and failure to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the investigation.
04/26/2026, 8:23 PM • GlobeNewswire
Heads Up! The Bear Cave Nails These Pump-And-Dump Stocks: QMMM, Cuprina, Pitanium, Mint And More
The Bear Cave financial newsletter warns about potential pump-and-dump stock schemes targeting thinly traded China-based stocks, with several companies experiencing unusual trading volume and significant price movements.
09/10/2025, 1:24 PM • Benzinga
Are You Holding These 6 Potential Pump-And-Dump Stocks? The Bear Cave Sees These As The Next Targets
The Bear Cave investigative newsletter warns of widespread pump-and-dump scams targeting U.S.-listed Chinese stocks, coordinated via WhatsApp groups and using fake investment tactics to manipulate stock prices.
08/11/2025, 12:28 PM • Benzinga
Peers
Statistics
MoreInformation as of 07/13/2026
Company Profile
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.
Key Executives
- Tat Jing Chan
- Ronald Sherman
- Yong Qi Quek
Current Ownership Distribution
- Insiders14.1M (99.38%)
- Institutions88,418 (0.62%)
- Mutual Funds0 (0.00%)
- Other0 (0.00%)